MPR Weekly Dose Podcast 84

The FDA grants Emergency Use to Actemra to treat hospitalized COVID patients. Revisions are been made to the fact sheets for the Moderna and Pfizer BioNTech COVID vaccines to include information related to the risk of myocarditis and pericarditis. A new treatment is approved for some cancer patients allergic to E. coli-Derived asparaginase products. Meanwhile,…

MPR Weekly Dose Podcast 83

This week the FDA approved a first-in-class switch for an antihistamine nasal spray, a new oral contraceptive, and Pradaxa was approved to prevent venous thromboembolism in pediatric patients. Also, we look at a published report on the real-world efficacy of the COVID-19 treatment remdesivir. 

MPR Weekly Dose Podcast 82

This week the FDA approved a regenerative skin tissue therapy and a treatment for advanced mastocytosis, while Novavax’s vaccine for COVID and a novel treatment for MDD show promise, also the FDA issue warning concering hand sanitizers.

MPR Weekly Dose Podcast 81

This week’s episode covers the aducanumab approval. There’s also approvals in treatments for obesity and a first treatment for Plasminogen Deficiency Type 1. Plus, Moderna have sent an EUA request to extend use of their COVID-19 vaccine to those aged 12 and older.

MPR Weekly Dose Podcast 79

This week we have news of changes to the storage of the Pfizer-BioNTech vaccine; A gene therapy gets Fast Track status by the FDA; Vitiligo cream shows promise in clinical trials; And outcomes in atherosclerotic cardiovascular disease are compared for different aspirin dosages.

MPR Weekly Dose Podcast 78

This week we have news of a COVID-19 vaccine authorization expansion for adolescents; A new postoperative pain treatment; There’s a new insulin smart pen devices; Insulin products are recalled; And the FDA grants fast track status to a potential treatment for the rare disease, FSHD.

MPR Weekly Dose Podcast 76

In this week’s pod, the FDA review the Emergency Use Authorization for bamlanivimab; Issues are identified at a Janssen manufacturing facility; Merck halts trials for investigational COVID therapy; A novel contraceptive is approved; And Ragwitek has its approval expanded.

MPR Weekly Dose Podcast 75

The latest status on the Janssen vaccine; Updated guidance from the National Institutes of Health on COVID-19 antibody treatment; The FDA changes in-person mifepristone dispensing; A prefilled-syringe for Xolair injection is approved; And the AI world comes to colonoscopies.

MPR Weekly Dose Podcast 74

Back to regular programming this week with a summary of the top news, which includes updated travel guidance; Six month efficacy data for the Moderna and Pfizer-BioNTech vaccines; Vial doses increased for Moderna; A new ADHD drug is approved; And the FDA has issued a safety communication regarding lamotrigine.